Aims and business model

The overall aim of Cardialysis is to make a contribution to the evaluation and development of potentially superior therapies and treatment strategies for cardiovascular disease. Cardialysis believes that the interest of the patient is best served by applying a business approach in drug and device development. Innovative trial methodologies, project management and partnerships are key elements to minimize the throughput time of drug and device development trials. For this purpose, Cardialysis brings together the better of two worlds:

  1. New concepts for drugs and devices or a combination of these from pharma/biotech and medical device organizations
  2. Expertise, skills and facilities in leading academic research centers and clinical investigational sites

Cardialysis' expertise and services are at the interface of these two worlds. Linking the leading clinical trial cardiologists from the continent and beyond, Cardialysis is at the forefront of the design and conduct of international clinical drug and device R&D programs in the field. In general, projects are conducted in collaboration with pharmaceutical/biotech or medical device companies, on the one hand, and carefully selected teams of investigators/institutes, on the other hand. Cardialysis navigates its partners through the array of (national) regulatory and institutional requirements to achieve the desired population and ultimately a successful clinical trial.